( August 20, 2026, 10:08 AM EDT) -- WASHINGTON, D.C. — The District of Columbia Circuit U.S. Court of Appeals held that a district court erred in part in rejecting Vanda Pharmaceuticals Inc.’s challenge to the U.S. Food and Drug Administration’s approval of labeling for generic tasimelteon and directed the court to remand the matter to the agency without vacating the approval....